false 0001379006 0001379006 2024-12-07 2024-12-07 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

 

FORM 8-K

 

CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF

THE SECURITIES EXCHANGE ACT OF 1934

 

Date of report (Date of earliest event reported) December 7, 2024

 

NANOVIRICIDES, INC.
(Exact Name of Registrant as Specified in Its Charter)

 

Delaware 001-36081 76-0674577
(State or Other Jurisdiction of
Incorporation)		 (Commission File Number) (I.R.S. Employer Identification No.)
     
1 Controls Drive,
Shelton, Connecticut		 06484
(Address of Principal Executive Offices) (Zip Code)

 

(203) 937-6137
(Registrant's Telephone Number, Including Area Code)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
   
¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
   
¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
   
¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ¨

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class:   Trading Symbol(s)   Name of each exchange on which registered:
Common Stock, par value $0.00001 per share   NNVC   NYSE-American

 

 

 

 

 

 

Item 5.07. Submission of Matters to a Vote of Security Holders.

On December 7, 2024, NanoViricides, Inc. (the “Company”) held its 2024 Annual Meeting of Stockholders (the “Meeting”). At the meeting, 6,096,059 shares of the Company’s common stock and 883,177 shares of Series A Convertible Preferred Stock (“Series A Preferred Shares”) entitled to vote at the Meeting, as of the record date of November 13, 2023, were present in person or by proxy, representing 47.1% of the Company’s outstanding voting capital stock and constituting a quorum for the transaction of business.

 

With a quorum present, the required shareholders approved the following proposals: (i) the re-election of Todd Rokita as a Class I Director and Makarand Jawadekar and Brian Zucker Class II Directors, each to a two-year term expiring at the 2026 annual meeting of stockholders and until their successor is duly elected and qualified or until their earlier resignation or removal; and (ii) the ratification of the appointment of EisnerAmper, LLP as the Company’s independent registered public accounting firm for the fiscal year ending June 30, 2025. Each proposal is described in more detail in the Company’s Proxy Statement filed with the Securities and Exchange Commission on October 15, 2024.

 

The voting results of the shares of the Company’s voting stock for each proposal are set forth below:

 

Proposal – Election of Directors - Re-Election of Theodore Rokita as a Class I Director and Makarand Jawadekar and Brian Zucker as Class II Directors:

 

Director  For   Against   Broker Non-Votes 
Theodore E. Rokita   2,060,147    166,389    3,813,361 
Makarand Jawadekar   1,951,381    272,416    3,813,361 
Brian Zucker   2,088,483    139,413    3,813,361 

 

Proposal 2 – Ratification of Accounting Firm – To ratify the appointment of EisnerAmper, LLP as the Company’s independent registered public accounting firm for the fiscal year ending June 30, 2025:

 

Votes For   Votes Against   Votes Abstained 
 5,757,913    230,937    107,209 

 

 

 

 

SIGNATURES

 

PURSUANT TO THE REQUIREMENTS OF THE SECURITIES EXCHANGE ACT OF 1934, THE REGISTRANT HAS DULY CAUSED THIS REPORT TO BE SIGNED ON ITS BEHALF BY THE UNDERSIGNED THEREUNTO DULY AUTHORIZED.

 

  NANOVIRICIDES, INC.
   
     
Date: December 12, 2024 By: /s/ Anil Diwan
  Name: Anil Diwan
  Title: Chairman, President

 

 

 

v3.24.3
Cover
Dec. 07, 2024
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Dec. 07, 2024
Entity File Number 001-36081
Entity Registrant Name NANOVIRICIDES, INC.
Entity Central Index Key 0001379006
Entity Tax Identification Number 76-0674577
Entity Incorporation, State or Country Code DE
Entity Address, Address Line One 1 Controls Drive
Entity Address, City or Town Shelton
Entity Address, State or Province CT
Entity Address, Postal Zip Code 06484
City Area Code 203
Local Phone Number 937-6137
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock, par value $0.00001 per share
Trading Symbol NNVC
Security Exchange Name NYSE
Entity Emerging Growth Company false
NanoViricides (AMEX:NNVC)
Historical Stock Chart
From Nov 2024 to Dec 2024 Click Here for more NanoViricides Charts.
NanoViricides (AMEX:NNVC)
Historical Stock Chart
From Dec 2023 to Dec 2024 Click Here for more NanoViricides Charts.